

JC525 U.S. PTO
10/80/11

Utility Patent Application Transmittal <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket Number	UCAL107DIV
		First Named Inventor	BISTRUP
		Title	GLYCOSYL SULFOTRANSFERASE-3
		Express Mail Label No.	EL923479227US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents</small>		ADDRESS TO: <small>Assistant Commissioner for Patents Box Patent Application Washington, DC 20231</small>	
<p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small></p> <p>2. <input type="checkbox"/> Applicant claims small entity status.</p> <p>3. <input checked="" type="checkbox"/> Specification <small>(preferred arrangement set forth below)</small></p> <ul style="list-style-type: none"> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R&D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claims(s) - Abstract of the Disclosure <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113)</p> <p>5. Oath or Declaration</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small></p> <p>i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)</small></p> <p>6. <input checked="" type="checkbox"/> Application Data Sheet, See 37 CFR 1.76</p>		Total Pages <div style="border: 1px solid black; display: inline-block; width: 20px; height: 20px; vertical-align: middle;"></div> 62	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
		8. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small> <ul style="list-style-type: none"> a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: <ul style="list-style-type: none"> i. <input type="checkbox"/> CD-Rom or CD-R (2 copies); or ii. <input type="checkbox"/> Paper c. <input type="checkbox"/> Statements verifying identity of above copies 	
ACCOMPANYING APPLICATION PARTS			
<p>9. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & documents(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <small>(when there is an assignee)</small> <input checked="" type="checkbox"/> Power of Attorney</p> <p>11. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(should be specifically itemized)</small></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small></p> <p>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). <small>Applicant must attach form PTO/SB/35 or its equivalent</small></p> <p>17. <input checked="" type="checkbox"/> Other: 1) Associate Power of Attorney (1 pg.) 2) Notification of Prior Sequence Listing (1 pg.)</p>			

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) of prior application No 09/190,911
Prior Application Information Examiner M. Moran Group Art Unit 1631

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

Fee Calculation						
CLAIMS AS FILED						
For	# Filed	# Allowed	# Extra	Rate	Fee	
Total Claims	20	20	0	x 18	\$0.00	
Indep. Claims	3	3	0	x 84	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>						
TOTAL CLAIM FEES						
BASIC FILING FEE					\$740.00	
OTHER FEE (specify purpose) Two (2) Assignment Recordations					\$80.00	
					TOTAL	\$820.00

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account 50-0815. If additional fees are required, including extensions of time, please consider this a petition therefore. A duplicate copy of this sheet is enclosed.



Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

19. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

19. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label



or Correspondence Address below

Name (Print/Type)	Paula A. Borden	PATENT & TRADEMARK	Registration No.	42,344
Signature			Date	11-08-2001
Firm Name	Bozicevic, Field & Francis LLP		Address	200 Middlefield Road, Suite 200
City	Menlo Park	State	California	zip 94025
Telephone - Direct Dial	650-833-7710		Fax	650-327-3231

**NOTIFICATION OF PRIOR SEQUENCE
LISTING**

Application Number	To Be Assigned
Confirmation Number	To Be Assigned
Filing Date	November 8, 2001
First Named Inventor	BISTRUP
Examiner	To Be Assigned
Group Art	To Be Assigned
Attorney Docket No.	UCAL107DIV

ADDRESS TO: Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The above-identified patent application contains sequences of nucleic acid and polypeptides. A sequence listing was prepared for parent application, **Serial No. 09/190,911, filed November 12, 1998**, in paper and computer-readable format. The sequences in the present application are identical to those presented in the parent application. Therefore, please transfer to this application, in accordance with 37 CFR 1.821(e), the computer readable copy from applicants' other application.

Applicants respectfully submit that the present patent application is now in compliance with 37 CFR 1.821 - 1.825.

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815. If additional fees are required, including extensions of time, please consider this a petition therefore.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

Name (Print/Type)	Paula A. Borden	Signature	Registration No.	42,344
Signature				Date 11-08-2001
Firm Name	Bozicevic, Field & Francis LLP		Address	200 Middlefield Road, Suite 200
City	Menlo Park	State	California	zip 94025
Telephone - Direct Dial	650-833-7710		Facsimile	650-327-3231

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage

Via Express Mail bearing Express Mail No. EL923479227US in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.

Name (Print/Type)	Margaret Pierce	Signature	M. Pierce	Date 11/08/2001
-------------------	-----------------	-----------	-----------	-----------------